![Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-13-00354/article_deploy/html/images/pharmaceuticals-13-00354-g004.png)
Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML
![Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-13-00354/article_deploy/html/images/pharmaceuticals-13-00354-g001.png)
Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML
![Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML Pharmaceuticals | Free Full-Text | IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-13-00354/article_deploy/html/images/pharmaceuticals-13-00354-g003.png)